Literature DB >> 14592343

Factor analysis of the International Restless Legs Syndrome Study Group's scale for restless legs severity.

Richard P Allen1, Clete A Kushida, Mark J Atkinson.   

Abstract

OBJECTIVE: The International Restless Legs Syndrome Study Group has developed and validated a ten-item scale for assessing the severity of the restless legs syndrome. This International Restless Legs Severity Scale (IRLS) is reported to have a high degree of internal consistency and it has generally been used as a single scale. This study uses a factor analytic approach to evaluate the IRLS for possibly useful subscales.
METHODS: A large convenience sample (n=516) of self-identified restless leg syndrome patients completed the IRLS over the Internet. Data were analyzed using principal component analyses.
RESULTS: Two primary factors were identified, one with six items related to symptom severity and a second with three items related to impact of the symptoms on life. These accounted for 41.8 and 22.5% of the variance, respectively.
CONCLUSIONS: The IRLS can be evaluated using separate subscale scores: one for symptoms and the other symptom impact. The relative merits of these subscale scores versus the score for the entire test need to be evaluated in different situations in further studies, in especially the ones involving assessing responsiveness to treatment effects.

Entities:  

Mesh:

Year:  2003        PMID: 14592343     DOI: 10.1016/s1389-9457(02)00193-4

Source DB:  PubMed          Journal:  Sleep Med        ISSN: 1389-9457            Impact factor:   3.492


  22 in total

1.  Restless legs syndrome: diagnostic assessment and the advantages and risks of dopaminergic treatment.

Authors:  Birgit Högl; Walter Paulus; Peter Clarenbach; Claudia Trenkwalder
Journal:  J Neurol       Date:  2006-08       Impact factor: 4.849

Review 2.  Genetic aspects of restless legs syndrome.

Authors:  V Dhawan; M Ali; K R Chaudhuri
Journal:  Postgrad Med J       Date:  2006-10       Impact factor: 2.401

3.  Association studies of variants in MEIS1, BTBD9, and MAP2K5/SKOR1 with restless legs syndrome in a US population.

Authors:  Qinbo Yang; Lin Li; Qiuyun Chen; Nancy Foldvary-Schaefer; William G Ondo; Qing Kenneth Wang
Journal:  Sleep Med       Date:  2011-09       Impact factor: 3.492

4.  Efficacy of an eight-week yoga intervention on symptoms of restless legs syndrome (RLS): a pilot study.

Authors:  Kim E Innes; Terry Kit Selfe; Parul Agarwal; Kimberly Williams; Kathryn L Flack
Journal:  J Altern Complement Med       Date:  2012-12-27       Impact factor: 2.579

5.  Sleep quality, depression, and quality of life in patients with pulmonary hypertension.

Authors:  Omar Batal; Omar F Khatib; Nancy Bair; Loutfi S Aboussouan; Omar A Minai
Journal:  Lung       Date:  2010-12-21       Impact factor: 2.584

6.  Genomewide linkage scan identifies a novel susceptibility locus for restless legs syndrome on chromosome 9p.

Authors:  Shenghan Chen; William G Ondo; Shaoqi Rao; Lin Li; Qiuyun Chen; Qing Wang
Journal:  Am J Hum Genet       Date:  2004-04-07       Impact factor: 11.025

7.  Demographic and clinical characteristics of patients with restless legs syndrome in spine clinic.

Authors:  Jin Seo Yang; Yong Jun Cho; Suk Hyung Kang; Hyuk Jai Choi
Journal:  J Korean Neurosurg Soc       Date:  2014-02-28

8.  A comparison of glycemic control, sleep, fatigue, and depression in type 2 diabetes with and without restless legs syndrome.

Authors:  Norma G Cuellar; Sarah J Ratcliffe
Journal:  J Clin Sleep Med       Date:  2008-02-15       Impact factor: 4.062

9.  The high prevalence of restless legs syndrome symptoms in liver disease in an academic-based hepatology practice.

Authors:  Rose A Franco; Ramesh Ashwathnarayan; Arshana Deshpandee; Joshua Knox; Jack Daniel; Daniel Eastwood; Jose Franco; Kia Saeian
Journal:  J Clin Sleep Med       Date:  2008-02-15       Impact factor: 4.062

10.  Validation of the Restless Legs Syndrome Quality of Life Instrument (RLS-QLI): findings of a consortium of national experts and the RLS Foundation.

Authors:  M J Atkinson; R P Allen; J DuChane; C Murray; C Kushida; T Roth
Journal:  Qual Life Res       Date:  2004-04       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.